Introduction
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that has earned a reputation among researchers as the cleanest and most selective of the commonly studied GHRPs. Its ability to stimulate growth hormone release without the cortisol, prolactin, and appetite side effects associated with other GHRPs makes it a particularly valuable research tool for isolating GH-specific effects in preclinical studies.
What Is Ipamorelin?
Ipamorelin (Ala-His-D-βNal-D-Phe-Lys-NH2) is a five-amino acid synthetic peptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. It was developed in the 1990s and characterized in landmark studies that established its selectivity profile compared to earlier GHRPs such as GHRP-6 and GHRP-2.
Selectivity Profile
The defining characteristic of Ipamorelin in research is its receptor selectivity. Unlike GHRP-6, which produces significant appetite stimulation and moderate cortisol and prolactin elevation, and GHRP-2, which produces stronger cortisol and prolactin responses, Ipamorelin stimulates GH release with minimal effect on cortisol or prolactin in animal studies. This selectivity was demonstrated in the original characterization studies and has been confirmed in subsequent research. For investigators seeking to study GH-mediated effects without the confounding variables of cortisol elevation or appetite changes, Ipamorelin is the preferred GHRP tool.
GH Release Kinetics
Ipamorelin produces a sharp, transient pulse of GH following administration, with a half-life of approximately 2 hours. The GH response mimics the pulsatile pattern of natural GH secretion, which is considered more physiologically relevant than continuous GH elevation. Research combining Ipamorelin with CJC-1295 (which acts on GHRH receptors) has demonstrated synergistic GH release, as the two compounds engage complementary receptor systems to amplify both the frequency and magnitude of GH pulses.
Research Applications
Ipamorelin has been used in preclinical research across several areas: GH secretagogue receptor pharmacology, body composition studies examining GH-mediated effects on fat and lean mass, bone density research, sleep architecture studies (given the relationship between GH and slow-wave sleep), and as a reference GHRP in comparative receptor selectivity studies.
Bone Research
Some of Ipamorelin’s most distinctive preclinical findings involve bone biology. Animal studies have shown significant increases in bone mineral content and cortical bone thickness with Ipamorelin administration, effects attributed to GH and IGF-1 elevation. These findings have positioned Ipamorelin as a research tool for studying GH-mediated bone metabolism.
Stability and Handling
Ipamorelin is supplied as a lyophilized powder, reconstituted with bacteriostatic water, and stored at standard peptide conditions. Its stability under recommended storage conditions is good, and it follows the general guidelines of 4 to 6 weeks post-reconstitution usability at 4°C.
Conclusion
Ipamorelin’s selectivity for GH release without meaningful cortisol or prolactin elevation makes it the cleanest available GHRP for research applications where those side effects would confound results. Its well-characterized receptor pharmacology, documented bone density effects, and synergistic action with GHRH analogues make it one of the most useful and widely referenced GH secretagogue research tools available.